Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05582135
Other study ID # XuanhanCo
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 5, 2021
Est. completion date August 16, 2021

Study information

Verified date October 2022
Source Xuanhan County People's Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study was to determine whether the addition of esketamine to morphine would improve postoperative analgesia after caesarean section. Parturients who planned for a caesarean delivery using combined spinal-epidural anaesthesia with a request for postoperative anaesthesia were randomly divided into four groups (A, B, C and D). When the surgery was completed, the parturients in groups A, B, C and D were administered 2 mg morphine, 0.25mg/kg of esketamine, 0.25mg/kg of esketamine plus 2 mg morphine sulfate and 0.25mg/kg of esketamine plus 1 mg morphine through the epidural catheters, respectively. The postoperative pain at rest, pain with movement, the number of rescue analgesics and adverse effects were evaluated for 48 h after caesarean delivery.


Recruitment information / eligibility

Status Completed
Enrollment 119
Est. completion date August 16, 2021
Est. primary completion date August 16, 2021
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 32 Years
Eligibility Inclusion Criteria: - nulliparous parturients who scheduled for elective caesarean delivery under spinal-epidural anaesthesia; - parturients who had requested postoperative analgesia; - parturients aged between 20-35 years old; - parturients who had a full-term pregnancy; - parturients who were identified as having a singleton pregnancy; and - parturients who were categorised as having an American Society of Anaesthesiologists (ASA) physical status Exclusion Criteria: - parturients with severe internal, surgical or obstetric comorbidities (including spinal deformities, hypertension, placental abruption, cholestasis in pregnancy, asthma, heart disease and abnormal coagulation parameters) - parturients with a known allergy to the drugs used in this study - parturients with severe mental illness who could not comply with doctors' instructions - parturients with chronic pain syndrome, which is defined as pain that persists for a period longer than 3 months

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
2 mg morphine sulfate
The parturients were administered 2 mg morphine sulfate through the epidural catheter. Sterile saline was added to make a total volume of 8 mL.
0.25mg/kg esketamine
The parturients were administered 0.25mg/kg of esketamine through the epidural catheter. Sterile saline was added to make a total volume of 8 mL.
0.25mg/kg of esketamine in combination with 2 mg morphine sulfate
The parturients were administered 0.25mg/kg of esketamine in combination with 2 mg morphine sulfate through the epidural catheter. Sterile saline was added to all combinations of the analgesic drugs to make a total volume of 8 mL.
0.25mg/kg of esketamine in combination with 1 mg morphine sulfate
The parturients were administered 0.25mg/kg of esketamine in combination with 1 mg morphine sulfate through the epidural catheter. Sterile saline was added to all combinations of the analgesic drugs to make a total volume of 8 mL.

Locations

Country Name City State
China Qijun Ran Dazhou Sichuan

Sponsors (1)

Lead Sponsor Collaborator
Xuanhan County People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Postoperative pain score at rest The pain scores at rest were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain. Two hours after caesarean delivery
Primary Postoperative pain score at rest The pain scores at rest were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain. Four hours after caesarean delivery
Primary Postoperative pain score at rest The pain scores at rest were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain. Eight hours after caesarean delivery
Primary Postoperative pain score at rest The pain scores at rest were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain. Twelve hours after caesarean delivery
Primary Postoperative pain score at rest The pain scores at rest were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain. Twenty-four hours after caesarean delivery
Primary Postoperative pain score at rest The pain scores at rest were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain. Forty-eight hours after caesarean delivery
Primary Postoperative pain score with movement The pain scores on movement were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain. Two hours after caesarean delivery
Primary Postoperative pain score with movement The pain scores on movement were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain. Four hours after caesarean delivery
Primary Postoperative pain score with movement The pain scores on movement were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain. Eight hours after caesarean delivery
Primary Postoperative pain score with movement The pain scores on movement were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain. Twelve hours after caesarean delivery
Primary Postoperative pain score with movement The pain scores on movement were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain. Twenty-four hours after caesarean delivery
Primary Postoperative pain score with movement The pain scores on movement were evaluated by the parturients themselves using a VAS based on a linear scale from 0 to 10, where 0 represented an absence of pain and 10 represented maximal pain. Forty-eight hours after caesarean delivery
Primary number of rescue analgesics required The number of rescue analgesics required within 48 h of surgery was recorded within Forty-eight hours of surgery
Secondary systolic blood pressure (SBP) Patient's systolic blood pressure (SBP) Two hours after caesarean delivery
Secondary systolic blood pressure (SBP) Patient's systolic blood pressure (SBP) Four hours after caesarean delivery
Secondary systolic blood pressure (SBP) Patient's systolic blood pressure (SBP) Eight hours after caesarean delivery
Secondary systolic blood pressure (SBP) Patient's systolic blood pressure (SBP) Twelve hours after caesarean delivery
Secondary systolic blood pressure (SBP) Patient's systolic blood pressure (SBP) Twenty-four hours after caesarean delivery
Secondary systolic blood pressure (SBP) Patient's systolic blood pressure (SBP) Forty-eight hours after caesarean delivery
Secondary diastolic blood pressure (DBP) Patient's diastolic blood pressure (DBP) Two hours after caesarean delivery
Secondary diastolic blood pressure (DBP) Patient's diastolic blood pressure (DBP) Four hours after caesarean delivery
Secondary diastolic blood pressure (DBP) Patient's diastolic blood pressure (DBP) Eight hours after caesarean delivery
Secondary diastolic blood pressure (DBP) Patient's diastolic blood pressure (DBP) Twelve hours after caesarean delivery
Secondary diastolic blood pressure (DBP) Patient's diastolic blood pressure (DBP) Twenty-four hours after caesarean delivery
Secondary diastolic blood pressure (DBP) Patient's diastolic blood pressure (DBP) Forty-eight hours after caesarean delivery
Secondary heart rate (HR) Patient's heart rate (HR) Two hours after caesarean delivery
Secondary heart rate (HR) Patient's heart rate (HR) Four hours after caesarean delivery
Secondary heart rate (HR) Patient's heart rate (HR) Eight hours after caesarean delivery
Secondary heart rate (HR) Patient's heart rate (HR) Twelve hours after caesarean delivery
Secondary heart rate (HR) Patient's heart rate (HR) Twenty-four hours after caesarean delivery
Secondary heart rate (HR) Patient's heart rate (HR) Forty-eight hours after caesarean delivery
Secondary Blood oxygen saturation (SpO2) Measurement of pulse Blood oxygen saturation (SpO2) in parturients Two hours after caesarean delivery
Secondary Blood oxygen saturation (SpO2) Measurement of pulse Blood oxygen saturation (SpO2) in parturients Four hours after caesarean delivery
Secondary Blood oxygen saturation (SpO2) Measurement of pulse Blood oxygen saturation (SpO2) in parturients Eight hours after caesarean delivery
Secondary Blood oxygen saturation (SpO2) Measurement of pulse Blood oxygen saturation (SpO2) in parturients Twelve hours after caesarean delivery
Secondary Blood oxygen saturation (SpO2) Measurement of pulse Blood oxygen saturation (SpO2) in parturients Twenty-four hours after caesarean delivery
Secondary Blood oxygen saturation (SpO2) Measurement of pulse Blood oxygen saturation (SpO2) in parturients Forty-eight hours after caesarean delivery
Secondary Adverse events Adverse events that occurred after the administration of study drugs were also recorded. within Forty-eight hours of surgery
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05534230 - Dexmedetomidine for Pain Reduction in CABG N/A
Recruiting NCT06275698 - HONEY for the Treatment of POst-Tonsillectomy Pain N/A
Recruiting NCT04436224 - Hydromorphone for ICU-analgesia in Patients With Non-mechanical Ventilation Phase 4
Not yet recruiting NCT04548323 - Hypoalgesic Effects of Walking and Running Imagined
Completed NCT06054945 - Clinical Impact of IPACK Block Addition to Suprainguinal Fascia Iliaca Block
Completed NCT04394481 - Extension of Analgesia by Combined Injection of Dexamethasone and Dexmedetomidine After Arthroscopic Shoulder Surgery Phase 4
Completed NCT04690647 - The Efficacy of Suprainguinal Fascia Iliaca Compartment Block for Analgesia After Elective Total Hip Replacement. N/A
Completed NCT05034601 - ESPB vs TPVB for Postoperative Analgesia After the Nuss Procedure N/A
Completed NCT03740815 - Feasibility of Serratus Plane Block Associated With Sedation in Axillary Dissection N/A
Recruiting NCT05454202 - Assessment of the Interest of ANI in the Non-communicating Patient in Palliative Care
Recruiting NCT04554186 - Serratus Anterior Plane Block Versus Thoracic Paravertebral Block. N/A
Not yet recruiting NCT06393777 - Effectiveness of Pre-administered Natural Sweet-tasting Solution (Honey) for Decreasing Pain of Needle Insertion N/A
Suspended NCT04860635 - Safety of F14 Following Total Knee Replacement Phase 2/Phase 3
Not yet recruiting NCT04519463 - The Effect of Local Anesthesia With Lidocaine During Insertion and Removal of Nasal Packing Early Phase 1
Completed NCT02916342 - Interscalene Block Versus Combined Supraprascapular: Axillary Nerve Blocks Phase 4
Not yet recruiting NCT02549118 - Tenoxicam for Intrapartum Analgesia Phase 2
Completed NCT03206554 - Local Infiltration Analgesia in Total Knee Arthroplasty Phase 2
Not yet recruiting NCT02190760 - Comparison Between Perineural and Systemic Effect of Dexamethasone for Interscalene Brachial Plexus Block. N/A
Completed NCT01789606 - Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet Phase 3
Completed NCT01299584 - ULTIVA Post Marketing Surveillance N/A